Leyre Urigüen

Leyre Urigüen

Auto-generated profile, based on publicly available information

Leyre Urigüen

Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2004 in Neuropharmacology
Verified
Journal Article
Closed access
LULeyre Urigüen
Leyre Urigüen
SPSandra Pérez-Rial
Sandra Pérez-Rial
CLCatherine Ledent
Catherine Ledent
TPTomás Palomo
Tomás Palomo
Jorge ManzanaresJorge Manzanares
Jorge Manzanares

4 August 2009 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
LULeyre Urigüen
Leyre Urigüen
MGM. Julia García-Fuster
M. Julia García-Fuster
LCLuis Callado
Luis Callado
BMBenito Morentin
Benito Morentin
RHRomano La Harpe
Romano La Harpe
JMJ Javier Meana
J Javier Meana

6 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OAOlatz Arteaga-Cabeza
Olatz Arteaga-Cabeza
MRMiren Revuelta
Miren Revuelta
LULeyre Urigüen
Leyre Urigüen
AÁAntonia Álvarez
Antonia Álvarez
HMHaizea Montalvo
Haizea Montalvo
EHEnrique Hilario
Enrique Hilario
Despite advances in neonatal care, hypoxic-ischemic brain injury is still a serious clinical problem, which is responsible for many cases of perinatal mortality, cerebral palsy, motor impairment and cognitive deficits. Resveratrol, a natural polyphenol with important anti-oxidant and anti-inflammatory properties, is present in grapevines, peanuts and pomegranates. The aim of the present work was to evaluate the possible neuroprotective effect of resveratrol when administered before or immediately after a hypoxic-ischemic brain event in neonatal rats by analyzing brain damage, the mitochondrial status and long-term cognitive impairment. Our results indicate that pretreatment with resveratrol protects against brain damage, reducing infarct volume, preserving myelination and minimizing the astroglial reactive response. Moreover its neuroprotective effect was found to be long lasting, as behavioral outcomes were significantly improved at adulthood. We speculate that one of the mechanisms for this neuroprotection may be related to the maintenance of the mitochondrial inner membrane integrity and potential, and to the reduction of reactive oxygen species. Curiously, none of these protective features was observed when resveratrol was administered immediately after hypoxia-ischemia.

27 April 2018 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
IIInés Ibarra-Lecue
Inés Ibarra-Lecue
IMIrene Mollinedo-Gajate
Irene Mollinedo-Gajate
JMJ Javier Meana
J Javier Meana
LCLuis Callado
Luis Callado
RAREBECA DIEZ ALARCIA
REBECA DIEZ ALARCIA
LULeyre Urigüen
Leyre Urigüen
Long-term use of potent cannabis during adolescence increases the risk of developing schizophrenia later in life, but to date, the mechanisms involved remain unknown. Several findings suggest that the functional selectivity of serotonin 2A receptor (5-HT2AR) through inhibitory G-proteins is involved in the molecular mechanisms responsible for psychotic symptoms. Moreover, this receptor is dysregulated in the frontal cortex of schizophrenia patients. In this context, studies involving cannabis exposure and 5-HT2AR are scarce. Here, we tested in mice the effect of an early chronic Δ9-tetrahydrocannabinol (THC) exposure on cortical 5-HT2AR expression, as well as on its in vivo and in vitro functionality. Long-term exposure to THC induced a pro-hallucinogenic molecular conformation of the 5-HT2AR and exacerbated schizophrenia-like responses, such as prepulse inhibition disruption. Supersensitive coupling of 5-HT2AR toward inhibitory Gαi1-, Gαi3-, Gαo-, and Gαz-proteins after chronic THC exposure was observed, without changes in the canonical Gαq/11-protein pathway. In addition, we found that inhibition of Akt/mTOR pathway by rapamycin blocks the changes in 5-HT2AR signaling pattern and the supersensitivity to schizophrenia-like effects induced by chronic THC. The present study provides the first evidence of a mechanistic explanation for the relationship between chronic cannabis exposure in early life and increased risk of developing psychosis-like behaviors in adulthood.

1 November 2018 in Biochemical Pharmacology
Verified
Journal Article
Open access
IIInés Ibarra-Lecue
Inés Ibarra-Lecue
FPFUENCISLA PILAR-CUELLAR
FUENCISLA PILAR-CUELLAR
CMCarolina Muguruza
Carolina Muguruza
EFEva Florensa-Zanuy
Eva Florensa-Zanuy
ÁDÁlvaro Díaz
Álvaro Díaz
LCLuis Callado
Luis Callado
Mental disorders have a high prevalence compared with many other health conditions and are the leading cause of disability worldwide. Several studies performed in the last years support the involvement of the endocannabinoid system in the etiopathogenesis of different mental disorders. The present review will summarize the latest information on the role of the endocannabinoid system in psychiatric disorders, specifically depression, anxiety, and schizophrenia. We will focus on the findings from human brain studies regarding alterations in endocannabinoid levels, cannabinoid receptors and endocannabinoid metabolizing enzymes in patients suffering mental disorders. Studies carried out in humans have consistently demonstrated that the endocannabinoid system is fundamental for emotional homeostasis and cognitive function. Thus, deregulation of the different elements that are part of the endocannabinoid system may contribute to the pathophysiology of several mental disorders. However, the results reported are controversial. In this sense, different alterations in gene and/or protein expression of CB1 receptors have been shown depending on the technical approach used or the brain region studied. Despite the current discrepancies regarding cannabinoid receptors changes in depression and schizophrenia, present findings point to the endocannabinoid system as a pivotal neuromodulatory pathway relevant in the pathophysiology of mental disorders.

1 June 2002 in Developmental Brain Research
Verified
Journal Article
Closed access
EREva M Romero
Eva M Romero
BFBeatriz Fernández
Beatriz Fernández
OSOnintza Sagredo
Onintza Sagredo
NBNURIA GOMEZ BLAS
NURIA GOMEZ BLAS
LULeyre Urigüen
Leyre Urigüen
MVM Paz Viveros
M Paz Viveros